Stockreport

Zenas' stock drops 51% despite lead asset's Phase III rare disease win [Yahoo! Finance]

Amgen Inc.  (AMGN) 
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
PDF The B-cell inhibiting monoclonal antibody (mAb) triggered a statistically significant 56% reduction in the risk of Immunoglobulin G4-related disease (IgG4-RD) flare-ups [Read more]